FMRP – the protein behind immunotherapy resistance
Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system…
November 21, 2022 - 6 minutes
CRISPR: A Promising Industry With Many Questions Unanswered
The gene-editing tool CRISPR-Cas9 has taken over the life sciences world since its development in 2012. CRISPR has changed the way biology research is done, simplifying and speeding up the study of diseases and the discovery of drugs, as well as having a huge impact on crop and food development. Among all its possible applications, the fact that CRISPR can be used to tweak the human genome has made it especially promising for previously difficult-to-treat diseases.
But how does CRISPR work? What kind of therapies are being developed? How is the genome-editing market evolving? And how are stakeholders navigating the complex intellectual property around this technology? Find out the answers to these questions and more on this page.
Show More
The Genome Editing Toolbox: ZFNS, TALENS, and CRISPR in Biomedicine
This report covers the industry’s most common genome-editing tools, like CRISPR-Cas9, provides exclusive insights by experts, looks at the market, and addresses future applications and challenges of genome-editing tools.
Go to ReportLatest CRISPR Articles
PACT Pharma reports data from CRISPR cancer study
PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing…
November 11, 2022 - 5 minutes
Companies with exclusive rights to CRISPR diagnostic methods sign agreement
Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S.…
November 4, 2022 - 3 minutes
The role of long-read sequencing in validating CRISPR outcomes
Neil Ward, general manager of PacBio EMEA With applications of CRISPR across the spectrum of…
October 20, 2022 - 3 minutes
CRISPR gene editing: a key tool for counteracting climate change
Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing…
October 17, 2022 - 6 minutes
Way to transform Cas-9 protein into spherical nuclear acid developed
A team of researchers at U.S. Northwestern University has developed a way to transform the…
October 17, 2022 - 4 minutes
Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth
Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30,…
October 17, 2022 - 2 minutes
PerkinElmer’s Horizon Discovery: the lowdown on base editing
PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and…
October 17, 2022 - 5 minutes
The challenges of translating CRISPR to the clinic
CRISPR-Cas9 is revolutionizing all facets of drug discovery, allowing for both a deeper understanding of…
October 17, 2022 - 6 minutes
CRISPR/Cas9: Challenges and outlook from an investor’s perspective
A Q&A with Fady Riad, CEO of consulting company Centurion Life Sciences. How did CRISPR/Cas9…
October 17, 2022 - 6 minutes
ChristianaCare spins out new gene-editing company CorriXR Therapeutics
ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics…
October 14, 2022 - 2 minutes
Growing hub Lithuania ready to welcome biotech sector to EFIB’22
On October 26 and 27 the Lithuanian capital, Vilnius, is hosting the European Forum for…
October 6, 2022 - 5 minutes
